Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals Digital Hospital

WeDoctor Partners with Shanghai Children’s Medical Center to Enhance Pediatric Care

Fineline Cube Jul 22, 2024

WeDoctor Holdings Ltd, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700)...

Company Drug

Bio-Thera Solutions Submits BLAs for Stelara Biosimilar BAT2206 to FDA and EMA

Fineline Cube Jul 22, 2024

Bio-Thera Solutions Ltd, a biopharmaceutical company based in Guangzhou, has announced the submission of Biologic...

Company

Novartis Delivers Strong Q2 2024 Results with 11% YoY Net Sales Increase

Fineline Cube Jul 19, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has released its financial results for the second...

Company Deals Drug

J&J Halts Development of Epilepsy Therapy ADX71149 After Phase II Trial Failure

Fineline Cube Jul 19, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a US-based multinational medical devices, pharmaceutical, and consumer packaged...

Company

Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales

Fineline Cube Jul 19, 2024

Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its...

Company Drug

Sino Biopharmaceutical Submits Market Approval Filing for CDK2/4/6 Inhibitor Culmerciclib in Breast Cancer

Fineline Cube Jul 19, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced the submission...

Company Drug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management

Fineline Cube Jul 19, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...

Hospital Policy / Regulatory R&D

China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing

Fineline Cube Jul 19, 2024

China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...

Company Drug

China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal

Fineline Cube Jul 19, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Drug

Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency

Fineline Cube Jul 19, 2024

Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...

Company Medical Device

MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval

Fineline Cube Jul 19, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Medical Device

Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach

Fineline Cube Jul 19, 2024

Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers

Fineline Cube Jul 19, 2024

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...

Company Medical Device

Shanghai Sanyou Medical’s Cervical Thoracic Internal Fixation System Earns NMPA Approval

Fineline Cube Jul 19, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a leading medical device company based in China,...

Company Deals

Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group

Fineline Cube Jul 19, 2024

Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech...

Company Deals

NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041

Fineline Cube Jul 19, 2024

NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical...

Policy / Regulatory

NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency

Fineline Cube Jul 18, 2024

The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process...

Company Drug

Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial

Fineline Cube Jul 18, 2024

Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...

Company Drug

Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment

Fineline Cube Jul 18, 2024

ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...

Company Deals

Roche’s Genentech Terminates Relay Therapeutics Collaboration for SHP2 Inhibitor

Fineline Cube Jul 18, 2024

In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a...

Posts pagination

1 … 381 382 383 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.